GT
UTHR icon

Greenleaf Trust’s United Therapeutics UTHR Stock Holding History

Greenleaf Trust’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$573K Sell
1,057
-72
-6% -$40.5K 0.01% 484
2026
Q1 		$669K Buy
1,129
+27
+2% +$13.4K 0.01% 428
2025
Q4 		$537K Buy
1,102
+53
+5% +$24.7K ﹤0.01% 482
2025
Q3 		$440K Sell
1,049
-72
-6% -$24.2K ﹤0.01% 527
2025
Q2 		$322K Sell
1,121
-18
-2% -$5.38K ﹤0.01% 610
2025
Q1 		$351K Sell
1,139
-13
-1% -$4.46K ﹤0.01% 595
2024
Q4 		$406K Buy
1,152
+13
+1% +$4.78K ﹤0.01% 562
2024
Q3 		$408K Buy
1,139
+15
+1% +$5.07K ﹤0.01% 569
2024
Q2 		$358K Buy
1,124
+31
+3% +$8.21K ﹤0.01% 562
2024
Q1 		$251K Sell
1,093
-196
-15% -$44.2K ﹤0.01% 666
2023
Q4 		$283K Buy
1,289
+133
+12% +$30.7K ﹤0.01% 610
2023
Q3 		$261K Sell
1,156
-80
-6% -$18.4K ﹤0.01% 626
2023
Q2 		$273K Buy
1,236
+306
+33% +$67.8K ﹤0.01% 622
2023
Q1 		$208K Buy
930
+49
+6% +$12.1K ﹤0.01% 723
2022
Q4 		$245K Buy
+881
New +$222K ﹤0.01% 654
2022
Q3 		– Sell
-867
Closed -$204K – 744
2022
Q2 		$204K Buy
+867
New +$176K ﹤0.01% 671

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Greenleaf Trust's UTHR Position: Q2 2026 in Review

Greenleaf Trust reduced its United Therapeutics (UTHR) stake by 6.4% in Q2 2026, selling an estimated $40.5K and leaving 1,057 shares worth $573K. The position accounts for 0.01% of the portfolio, ranked #484.

Greenleaf Trust first reported a position in UTHR in Q2 2022 and has held it in 16 quarters since. The position peaked at $669K in Q1 2026. 880 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Greenleaf Trust held 1,057 shares of United Therapeutics worth $573K as of Q2 2026.
  • Greenleaf Trust sold 72 United Therapeutics shares in Q2 2026, an estimated $40.5K.
  • United Therapeutics made up 0.01% of Greenleaf Trust's portfolio in Q2 2026, its #484 holding.
  • Greenleaf Trust first reported a position in United Therapeutics in Q2 2022 and has held it in 16 quarters since.
  • Greenleaf Trust's United Therapeutics position peaked at $669K in Q1 2026.
  • 880 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Greenleaf Trust's 13F filing for Q2 2026, filed 21 Jul 2026.